Ubs Group Ag Landos Biopharma, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.26 - $0.55 $1,535 - $3,247	5,904 Added 1574.4%	6,279 $1,000
Q4 2022 Feb 08, 2023	BUY	$0.22 - $0.51 $82 - $191	375 New	375 $0
Q2 2022 Aug 10, 2022	BUY	$0.6 - $1.5 $745 - $1,864	1,243 New	1,243 $1,000
Q1 2022 May 16, 2022	SELL	$1.44 - $5.22 $5,479 - $19,862	-3,805 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.7 - $15.0 $17,883 - $57,075	3,805 New	3,805 $18,000
Q2 2021 Aug 13, 2021	SELL	$9.26 - $12.53 $16,927 - $22,904	-1,828 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$9.47 - $16.26 $17,311 - $29,723	1,828 New	1,828 $18,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.